Is Gain Therapeutics Stock a Good Investment?
Gain Therapeutics Investment Advice | GANX |
- Examine Gain Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Gain Therapeutics' leadership team and their track record. Good management can help Gain Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Gain Therapeutics' business and its evolving consumer preferences.
- Compare Gain Therapeutics' performance and market position to its competitors. Analyze how Gain Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Gain Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Gain Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Gain Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Gain Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Excited | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Gain Therapeutics Stock
Researching Gain Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 1.07. Gain Therapeutics had not issued any dividends in recent years.
To determine if Gain Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Gain Therapeutics' research are outlined below:
| Gain Therapeutics is way too risky over 90 days horizon | |
| Gain Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 55.18 K. Net Loss for the year was (22.27 M) with loss before overhead, payroll, taxes, and interest of (11.46 M). | |
| Gain Therapeutics currently holds about 24.25 M in cash with (18.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04. | |
| Gain Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Mack Gene of 200000 shares of Gain Therapeutics at 2.29 subject to Rule 16b-3 |
Gain Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Gain Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Gain Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Gain Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Gain Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.21 | -0.17 | 0.04 | 19 | ||
2024-03-26 | 2023-12-31 | -0.32 | -0.36 | -0.04 | 12 | ||
2023-05-12 | 2023-03-31 | -0.39 | -0.43 | -0.04 | 10 | ||
2024-05-14 | 2024-03-31 | -0.29 | -0.22 | 0.07 | 24 | ||
2023-11-14 | 2023-09-30 | -0.45 | -0.37 | 0.08 | 17 | ||
2022-11-10 | 2022-09-30 | -0.46 | -0.38 | 0.08 | 17 | ||
2022-05-16 | 2022-03-31 | -0.37 | -0.28 | 0.09 | 24 | ||
2022-08-08 | 2022-06-30 | -0.31 | -0.43 | -0.12 | 38 |
Gain Therapeutics Target Price Consensus
Gain target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Gain Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most Gain analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Gain stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Gain Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationGain Therapeutics Target Price Projection
Gain Therapeutics' current and average target prices are 2.34 and 7.33, respectively. The current price of Gain Therapeutics is the price at which Gain Therapeutics is currently trading. On the other hand, Gain Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Gain Therapeutics Market Quote on 23rd of March 2025
Target Price
Analyst Consensus On Gain Therapeutics Target Price
Gain Therapeutics Analyst Ratings
Gain Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Gain Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Gain Therapeutics' financials, market performance, and future outlook by experienced professionals. Gain Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Gain Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Gain Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Gain Therapeutics backward and forwards among themselves. Gain Therapeutics' institutional investor refers to the entity that pools money to purchase Gain Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Springbok Capital Management, Llc | 2024-12-31 | 35.8 K | Ubs Group Ag | 2024-12-31 | 35.2 K | Bridgeway Capital Management, Llc | 2024-12-31 | 30 K | Royal Bank Of Canada | 2024-12-31 | 17.5 K | Benedict Financial Advisors, Inc. | 2024-12-31 | 16 K | Sandhill Capital Partners Llc | 2024-12-31 | 15.4 K | Sprott Inc. | 2024-12-31 | 14 K | Citadel Advisors Llc | 2024-12-31 | 11.6 K | Creekmur Asset Management Llc | 2024-12-31 | 4.4 K | Geode Capital Management, Llc | 2024-12-31 | 267.4 K | Vanguard Group Inc | 2024-12-31 | 177.1 K |
Gain Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 62.07 M.Market Cap |
|
Gain Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.09) | (1.14) | |
| Return On Capital Employed | (1.87) | (1.78) | |
| Return On Assets | (1.08) | (1.13) | |
| Return On Equity | (2.04) | (1.93) |
Determining Gain Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Gain Therapeutics is a good buy. For example, gross profit margin measures Gain Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Gain Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Gain Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Gain Therapeutics. Check Gain Therapeutics' Beneish M Score to see the likelihood of Gain Therapeutics' management manipulating its earnings.
Evaluate Gain Therapeutics' management efficiency
Gain Therapeutics has return on total asset (ROA) of (0.9413) % which means that it has lost $0.9413 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6314) %, meaning that it created substantial loss on money invested by shareholders. Gain Therapeutics' management efficiency ratios could be used to measure how well Gain Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.14 in 2025. Return On Capital Employed is likely to rise to -1.78 in 2025. At this time, Gain Therapeutics' Other Current Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.3 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 12.8 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.87 | 0.84 | |
| Tangible Book Value Per Share | 0.86 | 0.83 | |
| Enterprise Value Over EBITDA | (1.29) | (1.35) | |
| Price Book Value Ratio | 3.04 | 3.20 | |
| Enterprise Value Multiple | (1.29) | (1.35) | |
| Price Fair Value | 3.04 | 3.20 | |
| Enterprise Value | 36.5 M | 34.7 M |
Leadership effectiveness at Gain Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 0.142 |
Basic technical analysis of Gain Stock
As of the 23rd of March, Gain Therapeutics retains the Risk Adjusted Performance of 0.1139, downside deviation of 4.83, and Market Risk Adjusted Performance of 2.74. Gain Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Gain Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gain Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gain Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gain Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gain Therapeutics' Outstanding Corporate Bonds
Gain Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Gain Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Gain bonds can be classified according to their maturity, which is the date when Gain Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US36262BAA08 Corp BondUS36262BAA08 | View | |
| HLNLN 3125 24 MAR 25 Corp BondUS36264NAB01 | View | |
| HLNLN 3625 24 MAR 32 Corp BondUS36264FAM32 | View | |
| HLNLN 3375 24 MAR 29 Corp BondUS36264FAL58 | View | |
| HLNLN 4 24 MAR 52 Corp BondUS36264FAN15 | View | |
| HLNLN 3375 24 MAR 27 Corp BondUS36264FAK75 | View | |
| US36261NAA54 Corp BondUS36261NAA54 | View |
Understand Gain Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Gain Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1139 | |||
| Market Risk Adjusted Performance | 2.74 | |||
| Mean Deviation | 4.7 | |||
| Semi Deviation | 4.4 | |||
| Downside Deviation | 4.83 | |||
| Coefficient Of Variation | 841.55 | |||
| Standard Deviation | 6.11 | |||
| Variance | 37.3 | |||
| Information Ratio | 0.1282 | |||
| Jensen Alpha | 0.7334 | |||
| Total Risk Alpha | 1.18 | |||
| Sortino Ratio | 0.1622 | |||
| Treynor Ratio | 2.73 | |||
| Maximum Drawdown | 32.31 | |||
| Value At Risk | (8.06) | |||
| Potential Upside | 10.75 | |||
| Downside Variance | 23.3 | |||
| Semi Variance | 19.35 | |||
| Expected Short fall | (5.41) | |||
| Skewness | 1.01 | |||
| Kurtosis | 1.96 |
| Risk Adjusted Performance | 0.1139 | |||
| Market Risk Adjusted Performance | 2.74 | |||
| Mean Deviation | 4.7 | |||
| Semi Deviation | 4.4 | |||
| Downside Deviation | 4.83 | |||
| Coefficient Of Variation | 841.55 | |||
| Standard Deviation | 6.11 | |||
| Variance | 37.3 | |||
| Information Ratio | 0.1282 | |||
| Jensen Alpha | 0.7334 | |||
| Total Risk Alpha | 1.18 | |||
| Sortino Ratio | 0.1622 | |||
| Treynor Ratio | 2.73 | |||
| Maximum Drawdown | 32.31 | |||
| Value At Risk | (8.06) | |||
| Potential Upside | 10.75 | |||
| Downside Variance | 23.3 | |||
| Semi Variance | 19.35 | |||
| Expected Short fall | (5.41) | |||
| Skewness | 1.01 | |||
| Kurtosis | 1.96 |
Consider Gain Therapeutics' intraday indicators
Gain Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Gain Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Gain Therapeutics Corporate Filings
F4 | 21st of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 6th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 19th of September 2024 Other Reports | ViewVerify | |
FWP | 1st of July 2024 A written communication used by offering participants to offer securities to the public or to solicit securities transactions. | ViewVerify |
Gain Stock media impact
Far too much social signal, news, headlines, and media speculation about Gain Therapeutics that are available to investors today. That information is available publicly through Gain media outlets and privately through word of mouth or via Gain internal channels. However, regardless of the origin, that massive amount of Gain data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Gain Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Gain Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Gain Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Gain Therapeutics alpha.
Gain Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Gain Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Gain Therapeutics Corporate Management
| Gianluca Fuggetta | Principal Reporting | Profile | |
| Xavier Barril | Chief Officer | Profile | |
| Joanne Taylor | Senior Research | Profile | |
| Terenzio PharmD | Senior Operations | Profile | |
| Salvatore Calabrese | CFO Sec | Profile |
Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.